Challenges in conducting clinical trials in children: Approaches for improving performance

Expert Review of Clinical Pharmacology

Volumn 2, Issue 6, 2009, Pages 609-617

  Kern, Steven E ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Economics; Efficacy; Ethics; Modeling and simulation; Pediatric; Pharmacodynamics; Pharmacokinetic

Indexed keywords

CHILD; CHILD HEALTH; CLINICAL STUDY; DRUG INDUSTRY; DRUG LABELING; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG SCREENING; ECONOMIC ASPECT; GOVERNMENT REGULATION; HEALTH HAZARD; HUMAN; MEDICAL ETHICS; PHARMACODYNAMICS; REVIEW; SIMULATION;

EID: 70549097988     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.09.40     Document Type: Review

References (65)

1. Ward RM, Kauffman R. Future of pediatric therapeutics: reauthorization of BPCA and PREA. Clin. Pharmacol. Ther. 81, 477-479 (2007). (Pubitemid 46452311)
2. Saint-Raymond A. Straight talk with ... Agnes Saint Raymond. Interview by Genevive Bjorn. Nat. Med. 15, 354-355 (2009).
3. Saint-Raymond A, Seigneuret N. The European paediatric initiative: 1 year of experience. Paediatr. Drugs 11, 9-10 (2009).
4. Stanski DR, Orloff JJ. Communicating with the FDA: the 'third rail' of a new model for drug development. J. Clin. Pharmacol. 48, 144-145 (2008).
5. Baer GR, Nelson RM. Ethical challenges in neonatal research: summary report of the ethics group of the newborn drug development initiative. Clin. Ther. 28, 1399-1407 (2006). •• Overview of ethical issue pertaining to study of drugs in children.
6. Altavilla A, Giaquinto C, Ceci A. European survey on ethical and legal framework of clinical trials in paediatrics: results and perspectives. J. Int. Bioethique 19, 17-48, 121-122 (2008).
7. EMEA. Ethical Considerations for Clinical Trials on Medicinal Products Conducted With the Paediatric Population. European Medicines Association, London, UK (2008).
8. Chappuy H, Doz F, Blanche S, Gentet JC, Pons G, Treluyer JM. Parental consent in paediatric clinical research. Arch. Dis. Child. 91, 112-116 (2006). (Pubitemid 43362514)
9. Amin SB, McDermott MP, Shamoo AE. Clinical trials of drugs used off-label in neonates: ethical issues and alternative study designs. Account Res. 15, 168-187 (2008).
10. Chalumeau M, Treluyer JM, Salanave B et al. Off label and unlicensed drug use among French office based paediatricians. Arch. Dis. Child. 83, 502-505 (2000).
11. Kimland E, Bergman U, Lindemalm S, Bottiger Y. Drug related problems and off-label drug treatment in children as seen at a drug information centre. Eur. J. Pediatr. 166, 527-532 (2007). (Pubitemid 46643706)
12. Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin. Drug Saf. 5, 703-718 (2006). •• Thorough review of off-label use in pediatrics and the risk of this practice. (Pubitemid 44322888)
13. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349, 1157-1167 (2003). •• Comprehensive review of pharmacology differences between children and adults.
14. L'Homme R, Warris A, Gibb D, Burger D. Children with HIV are not small adults: what is different in pharmacology? Curr. Opin. HIV AIDS 2, 405-409 (2007). (Pubitemid 47254736)
15. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharmacokinet. 45, 931-956 (2006). •• Review of in vitro to in vivo scaling for predicting drug effect in children.
16. Johnson TN, Tucker GT, Rostami-Hodjegan A. Development of CYP2D6 and CYP3A4 in the first year of life. Clin. Pharmacol. Ther. 83, 670-671 (2008).
17. Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl. 11, 1481-1493 (2005). (Pubitemid 43072624)
18. Houghton PJ, Morton CL, Tucker C et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr. Blood Cancer 49, 928-940 (2007). (Pubitemid 350022448)
19. Johnson TN, Tanner MS, Tucker GT. Developmental changes in the expression of enterocytic and hepatic cytochromes P4501A in rat. Xenobiotica 32, 595-604 (2002).
20. Mahmood I, Green MD, Fisher JE. Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance. J. Clin. Pharmacol. 43, 692-697 (2003). (Pubitemid 36759146)
21. Rakhmanina NY, van den Anker JN. Pharmacological research in pediatrics: from neonates to adolescents. Adv. Drug Deliv. Rev. 58, 4-14 (2006).
22. Kern SE, Stanski DR. Pharmacokinetics and pharmacodynamics of intravenously administered anesthetic drugs: concepts and lessons for drug development. Clin. Pharmacol. Ther. 84, 153-157 (2008).
23. Ernest TB, Elder DP, Martini LG, Roberts M, Ford JL. Developing paediatric medicines: identifying the needs and recognizing the challenges. J. Pharm. Pharmacol. 59, 1043-1055 (2007). (Pubitemid 47265351)
24. Johnson TN. The problems in scaling adult drug doses to children. Arch. Dis. Child. 93, 207-211 (2008).
25. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: general principles. Eur. J. Pediatr. 165, 741-746 (2006). (Pubitemid 44440510)
26. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur. J. Pediatr. 165, 819-829 (2006). (Pubitemid 44627767)
27. Mahmood I. A Bayesian approach for the estimation of pharmacokinetic parameters in children. Am. J. Ther. 10, 88-92 (2003).
28. Mahmood I, Tammara V. A comparison of two sparse sampling population pharmacokinetic approaches for the estimation of pharmacokinetic parameters in children. Int. J. Clin. Pharmacol. Ther. 42, 240-245 (2004). (Pubitemid 38477440)
29. Meibohm B, Laer S, Panetta JC, Barrett JS. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. 7, E475-E487 (2005). (Pubitemid 43071326)
30. Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin. Pharmacokinet. 47, 231-243 (2008). •• Clinical application of modeling and simulation to pediatric studies.
31. Koren G, Kearns GL, Reed M, Pons G. Use of healthy children as volunteers in drug studies: the ethical debate. Clin. Pharmacol. Ther. 73, 147-152 (2003). (Pubitemid 36269665)
32. Spooner N, Lad R, Barfield M. Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method. Anal. Chem. 81, 1557-1563 (2009).
33. Baker-Smith CM, Benjamin DK Jr, Grabowski HG et al. The economic returns of pediatric clinical trials of antihypertensive drugs. Am. Heart J. 156, 682-688 (2008).
34. Li JS, Eisenstein EL, Grabowski HG et al. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA 297, 480-488 (2007).
35. Zajicek A. The National Institutes of Health and the Best Pharmaceuticals for Children Act. Paediatr. Drugs 11, 45-47 (2009).
36. Boots I, Sukhai RN, Klein RH et al. Stimulation programs for pediatric drug research - do children really benefit? Eur. J. Pediatr. 166, 849-855 (2007). •• Assesses the influence of adult medicine on pediatric exclusivity efforts to date. (Pubitemid 46988181)
37. Grieve J, Tordoff J, Reith D, Norris P. Effect of the pediatric exclusivity provision on children's access to medicines. Br. J. Clin. Pharmacol. 59, 730-735 (2005). (Pubitemid 40835509)
38. Koren G, Rieder M, MacLeod SM. The global alliance for pediatric pharmacology: the future is here and now. Paediatr. Drugs 11, 4-5 (2009).
39. Wade KC, Wu D, Kaufman DA et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob. Agents Chemother. 52, 4043-4049 (2008).
40. Smith PB, Benjamin DK Jr, Murphy MD et al. Safety monitoring of drugs receiving pediatric marketing exclusivity. Pediatrics 122, E628-E633 (2008).
41. Benjamin DK Jr, Smith PB, Murphy MD et al. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA 296, 1266-1273 (2006).
42. Lee K, Bacchetti P, Sim I. Publication of clinical trials supporting successful new drug applications: a literature analysis. PLoS Med. 5, E191 (2008).
43. Gobburu JV, Lesko LJ. Quantitative disease, drug, and trial models. Annu. Rev. Pharmacol. Toxicol. 49, 291-301 (2009).
44. Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu. Rev. Med. 59, 1-12 (2008). (Pubitemid 351287920)
45. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48, 303-332 (2008). •• Summary of allometric principles applied to pharmacokinetic modeling.
46. Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin. Pharmacokinet. 45, 1013-1034 (2006). •• Summary of physiologic based modeling for scaling to children. (Pubitemid 44436004)
47. Edginton AN, Theil FP, Schmitt W, Willmann S. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin. Drug Metab. Toxicol. 4, 1143-1152 (2008).
48. Johnson TN. Modelling approaches to dose estimation in children. Br. J. Clin. Pharmacol. 59, 663-669 (2005).
49. Mahmood I. Prediction of drug clearance in children: impact of allometric exponents, body weight, and age. Ther. Drug Monit. 29, 271-278 (2007). (Pubitemid 47262255)
50. Mahmood I. Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J. Pharm. Sci. 98(10), 3850-3861 (2009).
51. Garnett CE, Beasley N, Bhattaram VA et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J. Clin. Pharmacol. 48, 13-18 (2008). (Pubitemid 350292272)
52. Powell JR, Gobburu JV. Pharmacometrics at FDA: evolution and impact on decisions. Clin. Pharmacol. Ther. 82, 97-102 (2007).
53. Wang Y, Bhattaram AV, Jadhav PR et al. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. J. Clin. Pharmacol. 48, 146-156 (2008).
54. Barrett JS, Mondick JT, Narayan M, Vijayakumar K, Vijayakumar S. Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy. BMC Med. Inform. Decis. Mak. 8, 6 (2008). (Pubitemid 351327187)
55. Pons G, Treluyer JM, Dimet J, Merle Y. Potential benefit of Bayesian forecasting for therapeutic drug monitoring in neonates. Ther. Drug Monit. 24, 9-14 (2002). (Pubitemid 34106724)
56. Zuppa A, Vijayakumar S, Jayaraman B et al. An informatics approach to assess pediatric pharmacotherapy: design and implementation of a hospital drug utilization system. J. Clin. Pharmacol. 47, 1172-1180 (2007).
57. Anand KJ, Anderson BJ, Holford NH et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br. J. Anaesth. 101, 680-689 (2008).
58. Bouwmeester NJ, Anderson BJ, Tibboel D, Holford NH. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br. J. Anaesth. 92, 208-217 (2004). (Pubitemid 38159658)
59. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab. Pharmacokinet. 24, 25-36 (2009).
60. Johnson TN. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology 192, 37-48 (2003).
61. Johnson TN, Thomson M. Intestinal metabolism and transport of drugs in children: the effects of age and disease. J. Pediatr. Gastroenterol. Nutr. 47, 3-10 (2008).
62. Shiran MR, Proctor NJ, Howgate EM, Rowland-Yeo K, Tucker GT, Rostami- Hodjegan A. Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling. Xenobiotica 36, 567-580 (2006). (Pubitemid 44174445)
63. Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Prediction of intestinal first-pass drug metabolism. Curr. Drug Metab. 8, 676-684 (2007). (Pubitemid 47578116)
64. US FDA. Pediatric drug development. 2009 www.fda.gov/cder/pediatric/ index.htm (Accessed 30 April 2009)
65. PriceWaterhouseCoopers. Pharma 2020: virtual R&D. Which path will you take? www.pwc.com/pharma2020